GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...
The US group's division has reported a pre-tax profit of $39.5m (£30.6m) for the 12 months to 31 January, 2024, according to ...
This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news ...
Barclays lowered the firm’s price target on GSK (GSK) to 1,450 GBp from 1,550 GBp and keeps an Equal Weight rating on the shares.
LEMSIP and other popular cold and flu tablets should be pulled from Britain’s shelves because they don’t work, experts have ...
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...
Harvey Jones thought he was getting a bargain when he snapped up these too much-loved FTSE 100 dividend growth stocks. Now they're getting on his nerves.
Sony Pictures Networks India (SPNI) has appointed Sibaji Biswas as its new Chief Financial Officer (CFO), effective the first ...
The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.
In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares closed yesterday at ...
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback